The FDA made notable regulatory decisions at the end of the year, including the approval of the first drug for obstructive sleep apnea, a treatment for familial chylomicronemia syndrome, and a regenerative medicine option for trauma patients. Other approvals included drugs for atopic dermatitis, rare diseases, and cancer. However, there were rejections and warnings as well, with some drugs not meeting efficacy and safety requirements. Companies like Astellas, Applied Therapeutics, Intercept Pharmaceuticals, and Lexicon Pharmaceuticals faced setbacks. Overall, the end of the year brought a mix of good and bad news in the biotech industry.
Source link